Sutro Biopharma, Inc. (STRO) stock
Close on Nov 11, 2026Market cap $170.12MP/E –Yield –
Sutro Biopharma, Inc. saw revenue fall 56.3% to $45.70M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $170.12M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $170.12M
- P/E ratio
- –
- Price to sales
- 3.72
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $45.70M
- Net income
- -$180.64M
- EPS, diluted
- -$17.32
- Book value per share
- -$6.23
- Diluted shares
- 17M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $10.17
- Open
- $10.35
- Day's range
- $9.94 – $10.36
- Volume
- 138,935
- Average volume (20 days)
- 323,102
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 2.21
- 52-week range
- $7.15 – $43.85
- RSI (14 days)
- 42.4
- Volatility (1 year)
- 87.2%
- Relative volume
- 0.45×
- WACC
- 15.9%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | STRO | S&P 500 | Difference | STRO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.1% | -2.4% | −25.7 pts | ||
| 3 months | -59.0% | -1.2% | −57.9 pts | ||
| Year to date | -11.3% | +12.3% | −23.6 pts | ||
| 1 year | +26.2% | +12.4% | +13.7 pts | ||
| 3 years | -50.7% | +78.8% | −129.5 pts | -21.0% | +21.4% |
| 5 years | -95.0% | +75.2% | −170.1 pts | -45.0% | +11.9% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sutro Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- News
About Sutro Biopharma
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage oncology biotechnology enterprise dedicated to the design and development of novel-format and site-specific antibody-drug conjugates (ADCs) to treat solid tumors. Leveraging proprietary cell-free protein synthesis and site-specific conjugation platforms, known as XpressCF and XpressCF+, the organization creates homogeneous therapeutics, including standard ADCs, immunostimulatory ADCs, and dual-payload ADCs. Its clinical pipeline is led by STRO-004, an investigational therapy targeting tissue factor in patients with advanced solid tumors, alongside preclinical candidates STRO-227 and STRO-006. In addition to internal development, the firm partners with pharmaceutical and biotechnology companies through research, development, and licensing collaborations across oncology and infectious disease vaccine applications.
Company profile, executives and historySutro Biopharma stock: common questions
What is Sutro Biopharma's stock price?
STRO closed at $10.26 on Nov 11, 2026, up 0.88% on the day. Over the past 52 weeks it traded between $7.15 and $43.85.
What is Sutro Biopharma's market cap?
Sutro Biopharma was worth $170.12M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is STRO's P/E ratio?
Sutro Biopharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$17.32), so it has no meaningful P/E ratio.
How much revenue does Sutro Biopharma make?
Sutro Biopharma reported revenue of $45.70M for the twelve months to Jun 30, 2026, down 56.3% from a year earlier.
Does Sutro Biopharma pay a dividend?
No. Sutro Biopharma has not paid a cash dividend over the last twelve months.
When does Sutro Biopharma report earnings next?
Sutro Biopharma's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has STRO stock performed over the past year?
Including dividends, STRO returned +26.2% over the past year, against +12.4% for the S&P 500.
How many STRO shares are sold short?
2M shares were sold short at the latest FINRA report, 14.50% of the float, or 6.3 days of average trading volume.
Who are Sutro Biopharma's competitors?
Companies most similar to Sutro Biopharma by business, industry and size include CCCC, GLUE, CHRS, RXRX, CGEN.
See a number that looks wrong?